Your browser doesn't support javascript.
loading
Discovery of a Series of 7-Azaindoles as Potent and Highly Selective CDK9 Inhibitors for Transient Target Engagement.
Barlaam, Bernard; De Savi, Chris; Dishington, Allan; Drew, Lisa; Ferguson, Andrew D; Ferguson, Douglas; Gu, Chungang; Hande, Sudhir; Hassall, Lorraine; Hawkins, Janet; Hird, Alexander W; Holmes, Jane; Lamb, Michelle L; Lister, Andrew S; McGuire, Thomas M; Moore, Jane E; O'Connell, Nichole; Patel, Anil; Pike, Kurt G; Sarkar, Ujjal; Shao, Wenlin; Stead, Darren; Varnes, Jeffrey G; Vasbinder, Melissa M; Wang, Lei; Wu, Liangwei; Xue, Lin; Yang, Bin; Yao, Tieguang.
  • Barlaam B; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • De Savi C; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States.
  • Dishington A; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Drew L; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States.
  • Ferguson AD; Discovery Sciences, AstraZeneca, Boston, Massachusetts 02451, United States.
  • Ferguson D; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States.
  • Gu C; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States.
  • Hande S; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States.
  • Hassall L; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Hawkins J; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Hird AW; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States.
  • Holmes J; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Lamb ML; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States.
  • Lister AS; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • McGuire TM; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Moore JE; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • O'Connell N; Discovery Sciences, AstraZeneca, Boston, Massachusetts 02451, United States.
  • Patel A; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Pike KG; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Sarkar U; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States.
  • Shao W; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States.
  • Stead D; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Varnes JG; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States.
  • Vasbinder MM; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States.
  • Wang L; Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, P. R. China.
  • Wu L; Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, P. R. China.
  • Xue L; Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, P. R. China.
  • Yang B; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States.
  • Yao T; Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, P. R. China.
J Med Chem ; 64(20): 15189-15213, 2021 10 28.
Article en En | MEDLINE | ID: mdl-34647738
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Quinasa 9 Dependiente de la Ciclina / Inhibidores de Proteínas Quinasas / Descubrimiento de Drogas / Indoles Límite: Humans Idioma: En Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Quinasa 9 Dependiente de la Ciclina / Inhibidores de Proteínas Quinasas / Descubrimiento de Drogas / Indoles Límite: Humans Idioma: En Año: 2021 Tipo del documento: Article